deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04311515

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia

Sponsor: Samus Therapeutics, Inc.

Conditions Alzheimer Disease
Interventions Blood Biomarkers Cerebrospinal fluid (CSF) Biomarkers Fluorodeoxyglucose (FDG) Positron emission tomography (PET) PU-AD Placebo Rating Scales Tau Positron emission tomography (PET)
Updated 12 times since 2020 Last updated: Nov 14, 2022 Started: Jun 30, 2020 Primary completion: Sep 9, 2020 Completion: Nov 15, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Samus Therapeutics company closure

Other terminated trials from Samus Therapeutics, Inc.

More terminations from Samus Therapeutics, Inc.

Other Alzheimer Disease trials with similar outcome

Browse all Alzheimer Disease trials

Listed as NCT04311515, this PHASE2 trial focuses on Alzheimer Disease and remains terminated or withdrawn. Sponsored by Samus Therapeutics, Inc., it has been updated 12 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2020 – ~Aug 2020 · 4 months · monthly snapshotNot Yet Recruiting~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshotRecruiting~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshotRecruiting~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~May 2022 · 16 months · monthly snapshotActive Not Recruiting~May 2022 – ~Jun 2022 · 31 days · monthly snapshotTerminated~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshotTerminated~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshotSuspended~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  5. Sep 2022 — Dec 2022 [monthly]

    Suspended PHASE2

    Status: Terminated → Suspended

▶ Show 7 earlier versions

  1. Jun 2022 — Sep 2022 [monthly]

    Terminated PHASE2

  2. May 2022 — Jun 2022 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  6. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Apr 2020 — Aug 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Samus Therapeutics, Inc.
Data source: Samus Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations